Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

TCGA-AC-A23C-01A-12R-A169-07

— · A

d33fc4ef-17f7-5f9f-89d6-85a646358fac

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
A
subtype
A
overall_survival_months
20
os_event
false

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • PROTEIN_SECRETION+0.430
  • ANDROGEN_RESPONSE+0.280
  • PI3K_AKT_MTOR_SIGNALING+0.240
  • INTERFERON_ALPHA_RESPONSE+0.200
  • INTERFERON_GAMMA_RESPONSE+0.190
  • PEROXISOME+0.180
  • UV_RESPONSE_DN+0.120
  • BILE_ACID_METABOLISM+0.090
  • FATTY_ACID_METABOLISM+0.090
  • TGF_BETA_SIGNALING+0.090

Top 10 suppressed

  • ESTROGEN_RESPONSE_EARLY-0.400
  • MYC_TARGETS_V2-0.400
  • ESTROGEN_RESPONSE_LATE-0.360
  • HYPOXIA-0.340
  • MYOGENESIS-0.300
  • WNT_BETA_CATENIN_SIGNALING-0.300
  • TNFA_SIGNALING_VIA_NFKB-0.290
  • APICAL_SURFACE-0.270
  • ANGIOGENESIS-0.250
  • CHOLESTEROL_HOMEOSTASIS-0.240

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR25617870
breast-umap@18
—C0.771
2TCGA-55-7727-01A-11R-2170-07
lung-landscapes@6
—cohortMD20.753
3TCGA-44-5645-01A-01R-A278-07
lung-landscapes@6
—cohortMD20.744
4SJEPD031509_D1.RNA-Seq
medullo-epn-umap@date-based
EPNSupratentorial EPN0.725
5SRR25617900
breast-umap@18
—A0.719
6MNG642
mng-umap@100
——0.718
7MDT-AP-3269
medullo-epn-umap@date-based
MedMedulloblastoma0.717
8TCGA-A7-A26E-01A-11R-A277-07
breast-umap@18
—D0.716
9SRR9879266
lung-landscapes@6
—cohortMD20.716
10TCGA-44-3918-01A-01R-A278-07
lung-landscapes@6
—cohortMD20.714

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 19 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
PROTEIN_SECRETION0.430Remibrutinib— uncovered
ANDROGEN_RESPONSE0.280Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.240Inavolisib— uncovered
INTERFERON_ALPHA_RESPONSE0.200Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.190Idelalisib— uncovered
PEROXISOME0.180Idelalisib— uncovered
UV_RESPONSE_DN0.120Inavolisib— uncovered
BILE_ACID_METABOLISM0.090Inavolisib— uncovered
FATTY_ACID_METABOLISM0.090Inavolisib— uncovered
TGF_BETA_SIGNALING0.090Inavolisib— uncovered
APOPTOSIS0.070Idelalisib— uncovered
COMPLEMENT0.070Inavolisib— uncovered
HEME_METABOLISM0.070Temsirolimus— uncovered
NOTCH_SIGNALING0.070Inavolisib— uncovered
ALLOGRAFT_REJECTION0.060Idelalisib— uncovered
G2M_CHECKPOINT0.030Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.020Inavolisib— uncovered
MITOTIC_SPINDLE0.010Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.010Inavolisib— uncovered